MA37961A1 - Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation - Google Patents

Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Info

Publication number
MA37961A1
MA37961A1 MA37961A MA37961A MA37961A1 MA 37961 A1 MA37961 A1 MA 37961A1 MA 37961 A MA37961 A MA 37961A MA 37961 A MA37961 A MA 37961A MA 37961 A1 MA37961 A1 MA 37961A1
Authority
MA
Morocco
Prior art keywords
her2 antibodies
new therapeutic
therapeutic treatments
low fucosylation
fucosylation anti
Prior art date
Application number
MA37961A
Other languages
Arabic (ar)
English (en)
Inventor
Steffen Goletz
Antje Danielczyk
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of MA37961A1 publication Critical patent/MA37961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte au domaine de la cancérothérapie par anticorps anticancéreux. Cette invention, qui fait preuve d'une efficacité accrue, concerne plus particulièrement l'utilisation d'anticorps anti-her2 présentant des caractéristiques de glycosylation améliorées, en particulier une fucosylation réduite..
MA37961A 2012-12-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation MA37961A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197768 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (fr) 2012-07-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Publications (1)

Publication Number Publication Date
MA37961A1 true MA37961A1 (fr) 2016-06-30

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37961A MA37961A1 (fr) 2012-12-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Country Status (16)

Country Link
US (1) US20150166664A1 (fr)
EP (1) EP2874658A1 (fr)
JP (1) JP2015528802A (fr)
KR (1) KR20150036710A (fr)
CN (1) CN104394887A (fr)
AU (1) AU2013291964B2 (fr)
BR (1) BR112014032169A2 (fr)
CA (1) CA2875486A1 (fr)
EA (1) EA201590237A1 (fr)
IL (1) IL236714A0 (fr)
MA (1) MA37961A1 (fr)
MX (1) MX2015000730A (fr)
NZ (1) NZ701974A (fr)
SG (1) SG11201407841YA (fr)
WO (1) WO2014013019A1 (fr)
ZA (1) ZA201408938B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
JP2020512382A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体
US12103978B2 (en) * 2018-06-15 2024-10-01 Shanghai Miracogen Inc. Methods and materials for treating cancer
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
DK1522590T3 (da) 2000-06-28 2009-12-21 Glycofi Inc Fremgangsmåde til fremstilling af modificerede glykoproteiner
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
ES2542885T3 (es) * 2003-01-22 2015-08-12 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
WO2005053742A1 (fr) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
WO2005086875A2 (fr) * 2004-03-11 2005-09-22 City Of Hope Anticorps t84.66 anti-ace humanise et ses applications
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR101603632B1 (ko) 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
AU2010303415B2 (en) * 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Also Published As

Publication number Publication date
BR112014032169A2 (pt) 2017-08-01
CA2875486A1 (fr) 2014-01-23
CN104394887A (zh) 2015-03-04
EA201590237A1 (ru) 2015-05-29
WO2014013019A1 (fr) 2014-01-23
AU2013291964B2 (en) 2017-12-14
AU2013291964A1 (en) 2015-02-05
JP2015528802A (ja) 2015-10-01
KR20150036710A (ko) 2015-04-07
MX2015000730A (es) 2015-08-06
IL236714A0 (en) 2015-02-26
ZA201408938B (en) 2016-09-28
EP2874658A1 (fr) 2015-05-27
US20150166664A1 (en) 2015-06-18
SG11201407841YA (en) 2015-02-27
NZ701974A (en) 2018-03-23

Similar Documents

Publication Publication Date Title
CO2017005845A2 (es) Anticuerpos monoclonales aislados contra cd73
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
MA40713A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
EA201590987A1 (ru) Соединения и способы их применения
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
EA201590997A1 (ru) Соединения и способы их применения
MA43466A1 (fr) Traitements du cancer de l'utérus
EA201890915A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
TN2015000396A1 (en) Antibody drug conjugates
EA201400625A1 (ru) Антитела против pd-l1 и их применение
WO2014160160A3 (fr) Conjugués anticorps-médicaments
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
WO2013177187A3 (fr) Traitement de tumeur synergique avec du pk il-2 étendu et des agents thérapeutiques
MA37975A1 (fr) Inhibiteurs de synthase de glucosylcéramide
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
WO2015009726A3 (fr) Utilisations médicales d'agonistes de cd38
EP4406612A3 (fr) Conjugués anticorps-médicament anti-cd70
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
EA201591977A1 (ru) Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
WO2014163714A3 (fr) Conjugués médicament-anticorps
MA32900B1 (fr) Compose d'aminopyrazole